Intuitive Surgical (ISRG) has gained notable attention from Wall Street, reflected in
bullish views and several recent transactions by
investment advisory services and
wealth management firms. These include Beacon, VCI Wealth Management, and Avanza Fonder, among others, adding or reducing shares of the company. With
FDA clearance expanded for ISRG's
da Vinci SP, the future feasibility of ISRG could potentially transform. Numerous analysts have updated their
price targets and forecasts for ISRG, pointing towards anticipated growth. Recent
stock movements have been influenced by various factors, from management commentary to Q3 results, leading some to question the company's valuation. Despite this, multiple
buy opportunities have been identified for ISRG, backed by a
27% three-month share price climb. Regulatory approval has impacted investor outlooks, with positive news driving a surge. Conversely, some investors showed concern causing a decline in share price despite reporting strong results. As ISRG navigates its growth,
procedure growth, Q4 earnings forecast, and market trends are drawing investor attention, resulting in a further appraisal of ISRG's valuation after recent momentum.
Intuitive Surgical ISRG News Analytics from Fri, 03 Oct 2025 07:00:00 GMT to Sat, 27 Dec 2025 10:20:10 GMT -
Rating 8
- Innovation 7
- Rumor -4
